NanoViricides’ $8.65 Million Common Stock Offering


Olshan Frome Wolosky LLP acted as counsel to Aegis Capital Corp., as sole bookrunner and representative of the several underwriters, in NanoViricides’ offering.

NanoViricides, Inc. (NYSE American: NNVC) completed the $8.65 million follow-on equity public offering of 2,875,000 shares of common stock, including the underwriters’ full exercise of their 375,000 over-allotment option.

NanoViricides is a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform.

NanoViricides will use the net proceeds to provide valuable capital to help the company advance its drug pipeline into human clinical trials. NanoViricides anticipates filing an IND with the US FDA to advance NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication.

Founded in 1984, Aegis Capital Corp. is a premiere full-service investment banking firm with over twenty locations and employees stretching across the US.

The Olshan Frome team was led by corporate partner Spencer G. Feldman (Picture) and included corporate partner Kenneth A. Schlesinger and counsel Jason D. Cabico.

Involved fees earner: Jason Cabico – Olshan Frome Wolosky LLP; Spencer Feldman – Olshan Frome Wolosky LLP; Kenneth Schlesinger – Olshan Frome Wolosky LLP;

Law Firms: Olshan Frome Wolosky LLP;

Clients: Aegis Capital Corporation;